UroGen Pharma's (URGN) ZUSDURI treatment demonstrated a 64.5% 36-month duration of response in the pivotal ENVISION Phase 3 trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday.

The company said the median duration of response had not yet been reached at a median follow-up of 35.5 months, with 79.6% of patients achieving a complete response at three months and many remaining disease-free at three years based on Kaplan-Meier analysis.

The data support the durability of ZUSDURI without maintenance therapy, highlighting its potential as a non-surgical, in-office to repeated transurethral resection of bladder tumor procedures, UroGen Pharma added.